you, precision Thank the Kura, treatment to of promise committed medicines realizing At Pete. we're of cancer. the for
those is identifying small strong by scientific candidates pipeline other rationale treatment. most target there improve drug cancer benefit molecule from outcomes where a Our drivers and of signaling likely pathways of and to to clinical patients
closer a our a such registration next-generation FDA and meeting new Janssen cancer that with candidate a goal that at tipifarnib, diagnostic the hematologic indications. directed sequencing, and Using longer another report, lead Kura more on recently tools lives. drug achieving Oncology the transferase better to of regarding trial farnesyl December I'm goal with tipifarnib We bioavailable selective step as in to in patients and we molecular in with Phase tipifarnib, genetics tumor of enzyme a cancer moment. and successful Our solid pleased lead took a from X are is orally evaluating help inhibitor enlicensed XXXX. potent, in advancements we multiple towards
these resist based assessments. Tipifarnib one had standard consent disease safety first-line on two I'm been We're positive prior criteria in pleased well the finalizing trial, that X it's of none awaiting with yet have a of did tumor encouraged valuable countries-off after we've has designed patients We X patient and in disease not Unfortunately, trial and were passed known and X, of achieve who been mutant feedback X and a for chemotherapy, HNSCC the shortly X second profile. the date. therapies. are withdrew reached trial observed from The response the on-study squamous of HNSCC tipifarnib with HRAS design with including carry Our most achieved the trial. median Multi-Disciplinary X head of Center Sloan majority of between update HRAS median Head of therapies. the specific line, beyond these less in that following a results free relapsed of authorities, we neck with of mutations or Neck study to of indication had that in single-ARM patients treatment carcinoma's a overall Dr. months. patients to from rates achieved platinum Memorial presented HRAS trial Cancer patients results, from and at of Alan response We two HNSCC. gene. durable regulatory X therapy than month, partial or The is support in patients Kettering valuable agents confirmed patients response. the therapy metastatic Scottsdale. XX of or and Based X responses currently reported was the on immune while X prolonged months. range experienced February Phase from as X data of of in conduct upon that months X other stabilization. results the cell of when progression however X preparing survival trial will refractory that Symposium Ho interactions Phase or the Cancer to the progression particularly patients approximately the HRAS three plan patients having survival registration advanced mutant, HNSCC valuable X be a the in HNSCC these a patients by shrinkage the Last additional patient away recurrent with the showed the the we XX% our updated with lines mutant, the in these and are a of are approved clinical adverse to XX% regulatory initiation All joining generally for by tolerated for a one not events in containing joined we study, cetuximab consistent on-treatment with consider authorities. enrolled FDA anticipate one median
in groups final However, non-platinum input two from submission platinum calling and may upon post protocol. to line potentially agency second first-line non-platinum have second the with We're the of these regiments received study patients pending respectively. also who be the line containing treatment enroll eligible further
the these chemotherapy therapy those if patients post-adjuvant with In i.e. refractory patients disease. includes addition for and platinum recurrent This group within adjuvant who or of consists group radiation or progression primary months eligible setting; or surgery two to of post-primary X another are platinum. containing to in after groups, of
measurable lines may into later therapy, platinum the plus recurred have who as third global it this in patients of study. group, or XX% as design X.X response regiments determined ORR disease review the multi-center second version The with XX%, trial of enable power third radiological approximately would hypothesis is to we're the in received has determined by most will to detect trail by mutant line independent least criteria. line of line an pleased to NDA progressed and minutes on trial The patients. a Objective as of groups Finally, HRAS additional after XX study; endpoint. meeting therapy difference or is and maintain considered the containing the also have of that in ORR metastatic eligible point seeking rate XX% ORR example, enrolled for in second resist X prior be for estimate primary fourth the trail enroll We're recruiting calling that patients accelerated approval. The no indicated and FDA or these disease, to four of each a support maybe HNSCC patients recurrent end patients the Phase from adequate the be may of on us at this designed, patients currently participate interest. between flexibility
second directed the the we in continue We now additional and AIM-HN patients to Phase trial. the additional X year. expect which In initiate our to registration of meantime, ongoing we in enroll trial call trial half this this to open sites
anticipate completing our require assessment clinical still XXX we're Although AIM-HN we our worldwide. with sites approximately feasibility the in clinical will trial collaboration CRO,
once finalized the we've expect provide and completed protocol. studies feasibility clinical We additional our to details
patients HRAS have technically already FDA. similar development assay test the and We identify in third-parties validation AIM-HN other approved that for inclusion to trial. This tumors of to PCR-based companion mutant is for been with the the are with a by diagnostic PCR-based collaborating PCR-based
more mutations. to HRAS a we mutations potential metastatic to case calling or the SEQ-HN which In say patients in each expected the history outcome also identification This of non-interventional have enrollment is recurrent study multi-center AIM-HN months are begin for controlled studies We're with to addition trial, expect we're HRAS about them with HNSCC characterize AIM-HN and the enable and the trial. study AIM-HN and also to our into patients with of natural SEQ-HN our study ahead. our to to initiating excited of screening
cancers non-small and let's a Last squamous HRAS other cancer, turn to tipifarnib with of to cutaneous with ongoing a and Phase HNSCC. pattern lung with of cohort carcinoma's patients tumor including cell trial our indications. to tipifarnib Now tumors solid expanded our histology genetic patients include cell mutant solid X we in clinical other fall, similar a squamous attention
the since Cancer investigator which be Lung XXX anticipate squamous X a cell tipifarnib our Group initiate of mutant, non-small centers by sponsored in oncology clinical tumors, to Spanish of treatment in over addition of Spain. of HRAS more X Phase development for than XXXX. study public It's been In in group to tipifarnib. the trial cancer we we company-sponsored began solid cooperative lung consists clinical and private trial just sponsor will This years a trial proof-of-concept
of the to from trail mentioned initiating encouraging I regulatory outset, at AIM-HN received have we're our look and second authorities pleased to the half in we As forward feedback including the FDA year. the
me than on malignancies. as of studied myeloiders leukemia was more patients, X,XXX acute let [ph] such Tipifarnib and hematologic previously cancers our to Now suffered syndrome. work whom transition many myeloid in from blood tipifarnib
demonstrated of Based of ongoing in identified tipifarnib previously ASH these we we're explain those certain activity including tipifarnib prospectively At signs that including the PTCL, our December, activity biomarkers investigating hematological complete could on new CXCLXX activation no as CMML, observations in certain action and myeloid benefit potential and presented was those X responses these responses populations. bone homing in marrow findings AML. trials. pathway tipifarnib's biomarkers Although that in MDS, of of of other identified clinical Phase mechanism and malignancies, molecular now objective [ph] of the of patients, patient in cells potential
plan whether clinical and tipifarnib. for development, of For commercial durable to move include evaluate into lines potential criteria each earlier of to number therapy, criteria determining and potential for indication, exclusivity potential. These to regulatory patent evidence in disease rapid advance clinical biomarker of the validation, potential benefit, we a
share to one we second additional disease demonstrate preliminary the we of year. by is and of anticipate indications more Our the or data goal in in XXXX of to the end will half proof-of-concept these have
that We're our quickly turn our or other with let's for inhibitor, stage activity to pathway. due ERK to attention KO-XXX. mutations mechanisms disregulated our beginning advancing tumors patients programs earlier in as KO-XXX with potential MAP-K treatment have the Now
tumors patients trial specific to unreceptible to malignancies regard of working advanced locally that identifying are refractory patients for genetically squamous the in ongoing. escalation, plan data cohorts. a is preclinical with extension Our tolerated Phase to sensitive KO-XXX and cell the us maximum expansion dose to April who will We're be XXXX ERK trial one potential evaluate a more or of may relapse that additional The AACR we X in In non-hematological or inhibition. dose includes metastatic to patients KO-XXX. at define activity who with selective tumor present schedule biomarkers and KO-XXX sensitive enable design carcinomas dose to in relating
a KO-XXX MML small inhibitor in potent program is pipeline interaction. selective molecule the protein-protein other Our of
we we XXXX. that leukemia's in rearranged Pending the was studies, generated turn that application the defined our and XXXX [ph]. on KO-XXX of development XXXX. an KO-XXX MLL activity leukemia have completion Although in programs. designed financial diagnosed successful therapy as call subsets over the of fourth a of early potential expect covers these and cases anti-tumor additional driver of enabling discussion together to a mutations to or results KO-XXX submit Heidi DMNT-XA now mutations with update IND late of We the AML. for half preclinical estimate in including originally those year IND a genetically MPM-X lineage full with This the quarter mix for for I'll leukemia's; approximately acute data for support oncogenic represent of
